Immunopathology of Metastases in Patients of Colorectal Carcinoma Treated with Monoclonal Antibody 17-1A and Granulocyte Macrophage Colony-stimulating Factor

Jayant Shetye, Peter Ragnhammar, Maria Liljefors, Birger Christensson, Jan-Erik Frödin, Peter Biberfeld, and Håkan Mellstedt

Department of Oncology/Pathology [J. S., P. R., M. L., J-E. F., P. B.] and Laboratory of Tumor Immunology [J. S., H. M.], Karolinska Hospital, S-17176 Stockholm; Department of Pathology, Huddinge University Hospital, S-14186 Stockholm [B. C.]; and Department of Experimental Oncology, University Hospital Uppsala, S-75017 Uppsala [H. M.], Sweden

ABSTRACT

Twenty patients with metastatic colorectal carcinoma were treated with a single infusion (400 mg) of a mouse monoclonal antibody (IgG2a) against the tumor-associated antigen CO 17-1A and with a daily injection of granulocyte macrophage colony-stimulating factor (GM-CSF) for 10 days. The cycle was repeated every month. Metastases from 5 of the 20 patients biopsied on days 1 and 10 of the first two treatment cycles were studied by immunohistochemistry.

During treatment, neutrophils, monocytes, and T lymphocytes increased concordantly in the tumor as in the blood of the individual patient. Macrophages (CD68) and CD8 T cells infiltrated the tumor glands and displayed TIA-1-reactive cytotoxic granules. Neutrophils were seen mainly in areas of necrosis. Activated (HLA-DR+) CD4+ T cells were usually abundant in the stroma. During treatment, few natural killer cells were found in the tumor, contrary to the marked increase seen in blood. Our observations indicate that GM-CSF markedly recruited activated, tumor-infiltrating leukocytes, possibly representing antibody-dependent cellular cytotoxicity and cytotoxic T effector cells. The notion that combined antibody and GM-CSF therapy may also promote a T-cell antitumor response is further supported and advocated by our findings. The study lends further support to combining GM-CSF with monoclonal antibody-based therapy.

INTRODUCTION

The poor prognosis of metastatic CRC treated with chemotherapy obviates the need for alternative treatment modalities. Previous studies with MAbs, alone or in combination with other biological agents, indicated antitumoral effects in human xenografts and CRC patients (1–3).

Unconjugated MAbs can destroy tumor cells by various direct mechanisms, such as ADCC (4), complement-dependent cytolysis (5), and apoptosis (6), or indirectly by the induction of an idiotypic network response (antitumor immunity: Ref. 7). Patients treated with MAbs developed anti-idiotypic antibodies (ab2), which bound to the variable region of the therapeutic MAb (ab1; Ref. 8). According to the idiotypic network theory, within the ab1 variable region, there is a mimicry of the epitope that ab1 recognizes, i.e., the nominal antigen. Correspondingly, T cells (T3) against the idiotype of ab1 may also be induced (9). Such an ab2/T3 mimicry can subsequently evoke an anti-idiotypic response, with the production of anti-anti-idiotypic antibodies (ab3) and T cells (T2; Ref. 10), which may recognize the same epitope as ab1. Such idiotype responses are probably of significance for the antitumor effect of a therapeutic MAb (10).

The rationale for combining MAb17-1A (an anti-colon carcinoma MAb) with GM-CSF in the treatment of CRC is based on the pleiotropic effects of GM-CSF, including mobilization of progenitors from the bone marrow, increasing the number and cytotoxic capacity of granulocytes and monocyte/macrophages, as well as their cytokine production (11–15). The Fc receptor expression on killer cells is enhanced by GM-CSF (14–16). GM-CSF may also augment the induction of an idiotypic network response by activating antigen-presenting cells (17, 18). The induction of an ab3 and ab2 response was markedly enhanced in patients receiving MAb17-1A together with GM-CSF, as compared to those receiving MAb17-1A alone (8).

On the basis of our experience with MAb17-1A immunotherapy in vivo (19) and our in vitro results on GM-CSF together with MAb17-1A (15), a combined MAb17-1A and GM-CSF treatment protocol for patients with metastatic CRC was imple-
immuno-pathology of MAb-treated colorectal carcinoma.

**Patients, Materials, and Methods**

**Patients.** Twenty patients were entered in this Phase II trial of combined MAb17-1A and GM-CSF therapy (3). During treatment, consecutive biopsies could be taken from five patients. The clinical characteristics of these five patients are presented in Table 1. All patients had metastatic CRC and a Karnovsky index of >80%. The primary tumors expressed the antigen CO17-1A on >70% of the tumor cells. One patient had received chemotherapy and radiation 5 months prior to entering the study, and another had had chemotherapy 2 months before. The other patients were, except for primary surgery, untreated.

**Treatment Schedule.** Human recombinant GM-CSF (250 µg/m²) produced in *Escherichia coli* (Behringwerke AG, Marburg, Germany; specific activity, 5 × 10⁷ units/mg protein) was given s.c. daily for 10 days. On day 3, 400 mg of MAb17-1A (mouse IgG; Centocor, Malvern, PA) was infused iv. for 60 min. The treatment cycle was repeated every fourth week, for a total of four cycles (3).

**Criteria for Response.** To ascertain CR, PR, MR, and SD, the size of a metastatic lesion, as measured on a computed tomography scan, was calculated as a product of two perpendicular diameters. CR was defined as a complete disappearance of all radiological and biochemical evidence of tumor. A PR denotes a >50% decrease in size and a >50% decrease in the serum concentration of CEA, CA19-9, and CA50. A MR was defined as a 25–50% decrease in at least one tumor lesion and/or a >50% decrease in the serum concentration of CEA, CA19-9, and/or CA50 and no increase (>25%) in any lesion. SD was defined as no significant change (<25%) in the size of all measurable lesions and no significant change (<50%) in the serum concentration of CEA, CA19-9, and CA50 for at least 3 months, preceded by a progressive phase. Progressive disease was defined as a >25% increase in size of at least one measurable lesion and >50% increase in the serum concentration of CEA, CA19-9, and/or CA50 (3).

**Isolation of PBMCs.** On days 1 and 10 of each cycle of treatment, PBMCs (lymphocytes and monocytes) were obtained by centrifugation of heparinized venous blood on a Ficoll/Isopaque gradient (density = 1.077 g/ml; Pharmacia, Uppsala, Sweden). The PBMCs were washed three times in Hank’s Tris Solution before immunostaining (20).

**Immunoflow Cytometry Analyses.** Subpopulations of MNCs were analyzed by indirect immunofluorescence using absorbed FITC-conjugated goat antimouse antibodies (IgG; Becton Dickinson, Mountain View, CA) or rabbit antimouse antibodies (IgG) F(ab’)2 fragments (Dakopatts A/S, Copenhagen, Denmark).

**Table 1** Clinical characteristics and responses of five biopsied patients treated with MAb17-1A in combination with GM-CSF

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Age (yr)</th>
<th>Sex</th>
<th>Primary tumor</th>
<th>Stage at diagnosis†</th>
<th>Previous therapy</th>
<th>Metastatic site</th>
<th>Response</th>
<th>Survival (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>65</td>
<td>M</td>
<td>Rectum</td>
<td>D</td>
<td>Surgery</td>
<td>Liver, lymph nodes</td>
<td>PD†</td>
<td>18.5</td>
</tr>
<tr>
<td>2</td>
<td>51</td>
<td>M</td>
<td>Rectum</td>
<td>D</td>
<td>Surgery</td>
<td>Liver</td>
<td>PD</td>
<td>11</td>
</tr>
<tr>
<td>3</td>
<td>66</td>
<td>M</td>
<td>Rectum</td>
<td>B3</td>
<td>Surgery</td>
<td>s.c. (abdominal wall)</td>
<td>MR</td>
<td>9</td>
</tr>
<tr>
<td>4</td>
<td>69</td>
<td>M</td>
<td>Transverse colon</td>
<td>B3</td>
<td>Surgery</td>
<td>s.c. (abdominal wall)</td>
<td>PD</td>
<td>11</td>
</tr>
<tr>
<td>5</td>
<td>53</td>
<td>M</td>
<td>Sigmoid colon</td>
<td>C2</td>
<td>Surgery</td>
<td>Liver, s.c. (abdominal wall)</td>
<td>PD</td>
<td>17.5</td>
</tr>
</tbody>
</table>

† Modified Aster-Coller staging.

‡ Survival from start of therapy.

§ PD, progressive disease.

**Table 2** Antibodies used for immunohistochemical staining of biopsies from patients of metastatic colorectal carcinoma

<table>
<thead>
<tr>
<th>Antigen</th>
<th>CD</th>
<th>Antibody</th>
</tr>
</thead>
<tbody>
<tr>
<td>T cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pan-T</td>
<td>3</td>
<td>Leu 4*</td>
</tr>
<tr>
<td>T suppressor</td>
<td>8</td>
<td>Leu 2a*</td>
</tr>
<tr>
<td>T helper</td>
<td>4</td>
<td>Leu 3a*</td>
</tr>
<tr>
<td>IL-2 receptor</td>
<td>25</td>
<td>Anti-Tac b</td>
</tr>
<tr>
<td>M₆ 15,000 granule-associated protein</td>
<td></td>
<td>TIA-1</td>
</tr>
<tr>
<td>NK cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transmembrane form</td>
<td>16a</td>
<td>Leu 11*</td>
</tr>
<tr>
<td>FcyRIIIA/FcγR11B</td>
<td>57</td>
<td>Leu 7a*</td>
</tr>
<tr>
<td>HNK-1</td>
<td>68</td>
<td>KIM6d</td>
</tr>
<tr>
<td>Macrophages</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Granulocytes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mediators</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C3</td>
<td></td>
<td>Neutrophil elastasec</td>
</tr>
<tr>
<td>Mouse IgG</td>
<td></td>
<td>Antihuman C3d</td>
</tr>
<tr>
<td>Other MAbs</td>
<td></td>
<td>Biotinylated horse antimea</td>
</tr>
<tr>
<td>Cytokeratin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MHC I</td>
<td></td>
<td>HLA ABC (w6/32f)</td>
</tr>
<tr>
<td>MHC II</td>
<td></td>
<td>HLA DR (DK22)f</td>
</tr>
</tbody>
</table>

* Becton-Dickinson, Mountain View, CA.
  § TIA-1 was a generous gift from Stuart F. Schlossman, Department of Rheumatology and Immunology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA.
  † Behring AG, Marburg, Germany.
  †† Dakopatts A/S, Copenhagen, Denmark.
  † ICM Immunochemicals, Tumba, Sweden.
  † Boehringer Mannheim, Mannheim, Germany.
  † Different epitopes on the same molecule. GA 73-3 was used in parallel sections only for testing the eligibility of patients entering the trial.
  $ MAb17-1A and MAb GA 73-3 were generous gifts from Prof. Kowprowski, Institute of Biotechnology and Advanced Molecular Medicine, Thomas Jefferson University, Philadelphia, PA.

* Behring AG, Marburg, Germany.
Fig. 1 Total numbers (means) of lymphocytes (a; ●), monocytes (a; ○), and neutrophils (b; □) in five patients during the first two treatment cycles. GM-CSF was injected for 10 days (days 1–10), and MAb17-1A was injected on day 3.

Fig. 2 Columns, relative changes in the ratios (means) of neutrophils in peripheral blood and tumors of five patients during the first two treatment cycles. The values were calculated in comparison to day 1 of cycle I.

Fig. 3 Columns, relative changes in the ratios (means) of blood CD14+ monocytes and tumor CD68+ macrophages (CD68 expression tested in tumor) of five patients during the first two treatment cycles. The values were calculated in comparison to day 1 of cycle I.
Table 3  Relative changes in ratios (means) of T lymphocytes and NK cells in the peripheral blood and in the metastases of five colorectal carcinoma patients treated with MAb17-1A and GM-CSF

<table>
<thead>
<tr>
<th>Ratioa</th>
<th>CD3</th>
<th>CD16</th>
<th>CD57</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PBb</td>
<td>Biopsy</td>
<td>PB</td>
</tr>
<tr>
<td>CID10/CID1</td>
<td>1.0</td>
<td>2.98</td>
<td>5.53</td>
</tr>
<tr>
<td>CID1/CID1</td>
<td>1.71</td>
<td>1.31</td>
<td>1.23</td>
</tr>
<tr>
<td>CID10/CID1</td>
<td>1.85</td>
<td>2.0</td>
<td>1.68</td>
</tr>
</tbody>
</table>

The value at day 1 of cycle I (CID1) was used as baseline (1.0). CID10, cycle I, day 10; CID1, cycle I, day 1; CID10, cycle II, day 1; CID10, cycle II, day 10.

PB, peripheral blood.

Fig. 4  Columns, relative changes in the ratios (means) of CD8\(^+\) T cells in peripheral blood and tumor of five patients during the first two treatment cycles. The values were calculated in comparison to day 1 of cycle I.

Fig. 5  Columns, relative changes in the ratios (means) of CD4\(^+\) T cells in peripheral blood and tumors of five patients during the first two treatment cycles. The values were calculated in comparison to day 1 of cycle I.

with a washing (TBS) in between. The conjugates (200 µl) were preabsorbed overnight at 4°C with a solution A (10 µl) of the Immunoglobulin Standard Set (Immunodiagnostics, Boehringer Mannheim, GmbH, Mannheim, Germany) and centrifuged before use. The bound peroxidase was visualized by incubation (5–6 min) with a fresh chromogen substrate solution of dianaminobenzidine (30 mg/ml; Sigma Chemical Co., St. Louis, MO) in 50 ml of PBS buffer containing 0.03% H\(_2\)O\(_2\). After washing in tap water, the sections were counterstained with Mayer’s hematoxylin, dehydrated in increasing grades of alcohol and xylene, and mounted in Eukit (O. Kindler, GmbH & Co., Freiburg, Germany).

Controls. Cryostat sections of a tonsil were immunostained in parallel with the tumor biopsies (positive controls). To evaluate tissue reactivity of the conjugates, TBS was used (TBS control) instead of the primary antibody. TBS control was used for detection of cell-bound mouse MAb17-1A.

Evaluation of Immunohistochemical Staining. Coded biopsies were evaluated without knowledge of the patient’s clinical status or the time of the biopsy. A 1-cm grid (graticule) with 100 crosses (+) was inserted into the eye piece (×12.5) of the microscope, and the relative frequencies of “hits” (+) over tumor cells, stroma, and empty space were recorded. Counting was carried out under an oil immersion lens (×100). A total of 50 fields were counted. The infiltrating cells positive for particular phenotypes were counted in the stroma of the tumor in that field. The total number of hits on the stroma was divided by 100, which was the total number of stromal fields. The total number of MNCs in 50 fields was counted. The total number of MNCs divided by the total number of stromal fields was the average number of MNCs in one stromal field (unit).

The number of various WBC phenotypes in the pretreatment biopsy (CID1) and blood was considered as a baseline value. Ratios were calculated by comparing the baseline value (CID1) in the biopsy and the peripheral blood to the values in subsequent biopsies and peripheral blood (CID10, CID1, and CID10).

Evaluation of Complement Staining. During each treatment cycle, the pretreatment biopsy was compared to the respective posttreatment biopsy. Because the antigen, CO 17-1A, is strongly expressed in the basement membrane of tumor glands, we searched for complement deposition along the basement membrane of the tumor glands (22). The intensity of staining was scored on the following scale: negative, −; very weak, (+); weak, +; moderate, ++; and strong, +++.
The rise in blood neutrophil counts during both treatment cycles was similar (Fig. 2). A 2–3-fold increase in blood PBMCs, mainly monocytes (CD14+), was seen during the two treatment cycles (Fig. 3), whereas during the first treatment cycle, the numbers of CD3+, CD8+, and CD4+ T cells remained essentially unchanged. However, 4 weeks later, at the start of cycle II, the number of T cells [CD3+ (Table 3), CD8+ (Fig. 4), and CD4+ (Fig. 5)] was higher than baseline. During the second treatment cycle, the number of CD3+ and CD4+ (Fig. 5) T cells but not that of CD8+ T cells (Fig. 4) increased further. Cells expressing the interleukin 2 receptor (CD25), mainly lymphocytes, were also augmented at the end of each treatment cycle (data not shown), as were FcyRIII+ cells (CD16), whereas CD57+ NK cells were not significantly increased (Table 3).

**Immunohistochemistry of Metastases.** Eighteen biopsies from the five patients obtained during treatment showed viable tumor cells and were evaluated by immunohistochemistry as described below.

**Tumor-associated Antigens and MHC Class I/II Antigens.** Throughout the course of treatment, the intensity and the number of viable tumor cells reacting with MAb17-1A did not change measurably. Tumor cells in all of the metastases were positive for MHC class I but were negative for MHC class II antigens and did not show significant changes during therapy. In most biopsies, there was an increase in the number of intratumoral MNCs expressing MHC class II (HLA-DR) molecules in posttreatment biopsies, as compared to pretreatment biopsies (data not shown).

**Tumor-infiltrating Neutrophils.** An average of 0.87 neutrophil was seen per unit area of stroma in the pretreatment biopsies. A rise in neutrophils following therapy was seen during both cycles (Fig. 2). Infiltrating neutrophils were mainly found in areas of necrosis.

**Tumor-infiltrating Macrophages.** In the pretreatment biopsies, an average of 1.81 macrophages was seen per unit area of stroma. At day 10 of each treatment cycle (CID10 and CIID10), there was an increase in infiltrating CD68+ MNCs, mostly macrophages, as compared to the pretreatment biopsy (CID1; Fig. 3). The variation in the frequency of infiltrating macrophages followed that of blood monocytes (Fig. 3). In the posttreatment biopsies, cells expressing TIA-1 were usually more in number than CD8+ lymphocytes (Fig. 6, a and b). Thus, from a quantitative consideration, cells other than CD8+ lymphocytes appeared to express TIA-1. These MNCs were probably macrophages, as few, if any, NK cells were seen in the biopsies (Fig. 6c).

**Tumor-infiltrating T Cells.** In the pretreatment biopsies, an average of 0.92 CD3+ cell (0.42 CD4+ cell and 0.35 CD8+ cell) was observed per unit area of stroma. CD3+ T cells increased in the metastases during both therapy cycles (Table 3). The rise in intratumoral CD8+ T cells (an average of 0.60 CD8+ cell was seen per unit area of stroma in the posttreatment biopsies) appeared less marked compared to the blood levels (Fig. 4). The most intense infiltration of CD8+ cells was noted in the biopsies of CIID10, as compared to the pretreatment biopsies (CID1), i.e., ~5 weeks after initiation of GM-CSF/MAb17-1A treatment (Figs. 4 and 7).

In consecutive sections, CD8+ T cells appeared to stain for TIA-1 (Figs. 6, a and b). Similar to increase in the number of tumor infiltrating macrophages, neutrophils, and CD8+ cells, there was also an increase in the infiltration of TIA-1+ cells in the posttreatment biopsy, as compared to the pretreatment biopsy (Fig. 8). These activated CD8+ T cells were mostly located in close proximity to tumor cells. CD4+ T cells were also markedly increased in the tumor during both treatment cycles (an average of 0.92 CD4+ cell was seen per unit area...
of stroma in the posttreatment biopsies; Fig. 5) but were in contrast to CD8+ cells scattered in the stroma away from the tumor glands. From consecutive sections, it seems as if CD4+ T cells were not stained for TIA-1 (data not shown). The intratumoral rise in CD25 (interleukin 2 receptor)-expressing MNCs was not that marked compared to that seen in the blood (data not shown).

**Tumor-infiltrating NK Cells.** In the pretreatment biopsy, an average of 0.07 NK cell (CD16+.CD56+.CD57+) was seen per unit area of stroma. In contrast to peripheral blood, very few CD16+.CD56+. and CD57+ NK cells were observed to infiltrate the metastases (Table 3) at any time both before and during the entire treatment period. The few infiltrating NK cells present in the metastases were randomly distributed.

Fig. 7 Sequential biopsies from one patient of a metastatic CRC lesion immunostained with MAb CD8. Note the gradual increase in number of CD8+ T cells (dark staining) in the stroma of the tumor during the entire course of treatment. Arrows, lightly hematoxylin-counterstained tumor glands. ×250. a, CID1; b, CID10; c, CID1; d, CID10.
DISCUSSION

Mouse IgG Antibody (MAb7-1A) and Complement.

In all five MAb7-1A-treated patients, mouse IgG antibody was not detected in the day 10 biopsies after treatment cycles I and II (CID10 and CIID10), whereas in four of five patients, posttreatment biopsies (CID10 and CIID10) showed deposition of C3. (Fig. 9) The poorly differentiated metastatic tumor of one patient did not show any complement deposition. The complement deposition was seen mainly along the basement membrane of the tumor glands, where the antigen CO 17-1A was maximally expressed. Occasionally, some complement deposition was also observed in areas of necrosis. In a few areas, tumor cells appeared to be covered by complement. All pretreatment biopsies were negative for C3, except at sites of necrosis. No complement deposition was observed in the biopsy taken prior to the second cycle of treatment (CIID1). The staining intensity of bound complement was mild (+) to moderate (+ +) after the first treatment (CID10), whereas the intensity was weaker after the second course (CIID10).

DISCUSSION

To our knowledge, this is the first immunohistochemical study of the local immune response in metastases of CRC patients treated with a combination of MAb7-1A and GM-CSF in relation to changes in neutrophils and MNC phenotypes of peripheral blood.

As reported previously, of the 20 patients treated with a combination of MAb7-1A and GM-CSF, 2 patients (10%) had a CR. The overall response rate (CR + PR + MR + SD) was 30% (2). Of the five patients reported in this study, only one showed a MR; the other four had progressive disease, with a median survival of 11 months. The number of patients biopsied were too few, precluding a statistical clinicopathological correlation. However, the patient that achieved a MR had a moderately differentiated tumor and showed the most pronounced infiltration of CD8 T cells (0.78 cell/unit area of stroma) and CD4 T cells (0.98 cell/unit area of stroma), as well as deposition of C3, in comparison to the other four posttreatment biopsies.

Seven days after a single infusion of 400 mg of MAb7-1A, we were not able to detect MAb7-1A. On the basis of the mild to moderate pattern of complement deposition, mouse IgG should have been bound to the tumors, but the relatively low amount of infused mouse IgG and the delayed interval of the posttreatment biopsy probably precluded its detection by the current staining technique. However, the amount of infused
1928 Immunopathology of MAb-treated Colorectal Carcinoma


The observed infiltration of T cells, both CD8+ and CD4+ subsets, into the tumors, particularly CD8+ cells at the beginning of the second cycle, seems to indicate a selective stimulatory effect by MAb17-1A and GM-CSF on T cells in between the two treatment cycles. These CD8+ cells might represent cytotoxic T cells because they were located around the tumor gland and expressed cytoxic TIA-1+ granules. The increased number of CD4+ cells observed in the tumor may reflect an increased helper function. This is in agreement with similar observations reported following MAb therapy in non-Hodgkin's lymphoma, malignant melanoma, and also CRC following MAb17-1A therapy (22, 25, 26). Such an increase in intratumoral CD4+ T cells seemed to correlate favorably to the clinical outcome (27, 28). The observed T-cell response in the treated CRC patients could reflect a cellular antitumor response partly induced by the idiotypic network (9, 29–31), in agreement with observations of an increased humoral idiotypic network response after MAb17-1A and GM-CSF treatment (8).

T cell-mediated tumor cell destruction is dependent on the exposure of target epitopes by MHC class I antigens on the tumor cells, whereas MHC class II molecules (HLA-DR), found on professional antigen presenting cells and also possibly on tumor cells, are required for the activation of helper CD4+ T cells. Tumor-infiltrating antigen-presenting cells may process and present tumor antigens from destroyed tumor cells. It is of interest to note that the two patients enrolled in this trial who achieved a CR after treatment (3) had both MHC class I and MHC class II expression on tumor cells, whereas the five patients in this study expressed MHC class I but not MHC class II on their tumor cells. Nevertheless, the present therapy regimen was effective in recruiting tumor-infiltrating CD4+ T cells, a subtraction of which may contain cells that are able to lyse tumor cells (32). Indeed, the lack of class II expression does not preclude induction of a cellular immune response because GM-CSF may activate locally professional antigen-presenting cells that can induce CD4+ T cells and, subsequently, initiate a cytotoxic CD8+ T-cell response (33).

In summary, combination immunotherapy of GM-CSF and MAb induced a marked recruitment into the tumor metastases of effector cells that are capable of participating in ADCC and CTL activity, further supporting the usefulness of GM-CSF in protocols with therapeutic monoclonal antibodies.

ACKNOWLEDGMENTS

We thank Åsa Edwardsson for technical help, Ingeborg May for the photomicrographs, and Lena Gahne for secretarial help. This study was approved by the Ethical Committee of the Karolinska Institute. MAb17-1A was a gift from Professor H. Koprowski, Institute of Biotechnology and Advanced Molecular Medicine. Thomas Jefferson University, Philadelphia, PA.

REFERENCES


Unpublished data.


Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor.

J Shetye, P Ragnhammar, M Liljefors, et al.